Theralink Technologies Inc (THER)

[budfoxfun]

BATON ROUGE, LA--(Marketwired - February 02, 2017) - OncBioMune Pharmaceuticals, Inc. (OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, is pleased to announce that the Company's abstract illustrating research on its novel therapeutic cancer vaccine, has been accepted for a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2017 in Washington, D.C.

The technology being presented at AACR serves as the foundation for ProscaVax, the Company's novel therapeutic cancer vaccine currently in a Phase 1 clinical trial funded in part by the Department of Defense, with a Phase 2 trial planned at a prominent cancer research university in the Northeast U.S. and a Phase 2/3 nearing enrollment in Mexico through a Joint Venture with the Company's acquisition target Vitel Laboratorios S.A. de C.V.